OCU400 is the first gene therapy from the biotechnology company to move forward into Phase 3 with a broad retinitis pigmentosa (RP) indication
The two products, both manufactured by Amgen, are aflibercept biosimilars Pavblu and Skojoy. Both biosimilars are indicated for treatment of AMD.
The company offers year-round educational services on the conditions, using this month in particular to guide patients to needed resources.
Pavblu and Skojoy, both from Amgen, are indicated for the treatment of neovascular age-related macular degeneration
Results from the study assisted Notal Vision in receiving De Novo authorization from the US FDA for the SCANLY Home OCT in 2024.
Previous research has shown that voretigene neparvovec administered subretinally early in childhood for RPE65-mediated inherited retinal dystrophy achieved encouraging efficacious results.
Laru-zova is a gene therapy currently being investigated for the treatment of patients with X-linked retinitis pigmentosa.
The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections.
The device recently received 510(k) clearance from the US Food and Drug Administration.
The main outcomes were the measurements of the visual acuity and visual field defects.
As Ophthalmology Times celebrates 50 years of publication and the Wilmer Eye Institute marks 100 years of academic leadership, Peter J. McDonnell, MD, reflects on their shared commitment to helping ophthalmologists improve patient outcomes.
Investigators examined the connection between amblyopia, components of the metabolic syndrome and individual cardiometabolic diseases.
Among these eyes, 18.9% of eyes developed nAMD within 36 months.
Previous research has shown that voretigene neparvovec administered subretinally early in childhood for RPE65-mediated inherited retinal dystrophy achieved encouraging efficacious results.
The lead gene therapy candidate, AXV-101, is expected to enter clinical development in mid-2025
The scientific outputs from MACUSTAR’s study could impact more than 200 million patients with AMD globally
Zhaoke Ophthalmology Limited is responsible for developing and obtaining regulatory approval for NVK-002 in Greater China, South Korea, and the Southeast Asian territories.
The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye.
Investigators examined the connection between amblyopia, components of the metabolic syndrome and individual cardiometabolic diseases
The program will deliver a range of high-quality access and affordability services for retina specialists.
The extension includes lenses that range from minus power of -13.00 diopters to cylindrical power up to 4.00 diopters
Among these eyes, 18.9% of eyes developed nAMD within 36 months.
The approval of Syfovre makes it the first and only approved treatment for GA in Australia.
The approval of Syfovre makes it the first and only approved treatment for GA in Australia.
Recipients will be awarded $100,000 to support a collaborative project related to glaucoma
The companies will work together by using the codon-optimized BBS1 AAV9 vector to minimize the vision loss caused by the genetic defects in the BBS1 gene.
The centre will facilitate research and access to resources for the 450,000 residents of the UK who are affected by sight and hearing loss
The AI-READI project aims to establish fair, equitable, and ethical access to big data, enhancing artificial intelligence’s ability to diagnose systemic diseases and drive progress in ophthalmology research.
The company states LYNX is the world’s first and only pattern scanning laser indirect ophthalmoscope and is battery-powered to provide surgeons with an untethered laser solution.